Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.

Saved in:
Bibliographic Details
Title: Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Authors: Singh H; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Srour SA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., McCarty J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dai C; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gaballa MR; Cellular Therapy Program and Bone Marrow Transplant Unit, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States., Ammari M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Olivares S; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Huls H; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., De Groot E; Alaunos Therapeutics, Boston, MA, United States., Marin D; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Petropoulos D; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Olson AL; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Anderlini P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Im JS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Khouri I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Hosing CM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cooper LJN; Alaunos Therapeutics, Boston, MA, United States., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Source: Frontiers in immunology [Front Immunol] 2022 Nov 10; Vol. 13, pp. 1032397. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2022.1032397